Brink Therapeutics
Biotechnology Research • • 1-10 Employees
Company overview
| Headquarters | XX |
| Website | |
| NAICS | 541714 |
| Founded | 2024 |
| Employees | 1-10 |
| Socials |
Key Contacts at Brink Therapeutics
Jonathan Naccache
Ceo & Co-Founder
Harry Kemble
Cto & Co-Founder
Brink Therapeutics Email Formats
Brink Therapeutics uses 2 email formats. The most common is {first initial}{last name} (e.g., jdoe@brinktx.com), used 60% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}{last name} | jdoe@brinktx.com | 60% |
{first name}{last name} | johndoe@brinktx.com | 40% |
About Brink Therapeutics
Brink Therapeutics is developing next-generation recombinases — ultra-precise and efficient enzymes that surpass CRISPR-Cas9. We aim to revolutionize Cell and Gene therapies, enabling large-scale production to treat cancer, genetic disorders, and other diseases.
Brink Therapeutics revenue & valuation
| Annual revenue | $598,885 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $2,000,000 |
| Total funding | $4,000,000 |
Employees by Management Level
Total employees: 1-10
Seniority
Employees
Employees by Department
Brink Therapeutics has 4 employees across 2 departments.
Departments
Number of employees
Funding Data
Explore Brink Therapeutics's funding history, including investment rounds, total capital raised, and key backers.
Germany
United States
Frequently asked questions
4.8
40,000 users
